^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    OncoKitDx

    Company:
    Healthincode
    Type:
    CE Marked
    Details
    Evidence

    News

    2ms
    Clinical implications of next generation sequencing for the classification of endometrial carcinoma (ECP 2024)
    Molecular characterization of endometrial carcinoma into subgroups has important implications for prognosis and treatment. Next-generation sequencing is a powerful tool that provides reliable results consistent with surrogate immunohistochemical markers. By performing a molecular profile of patients, NGS can identify important genetic mutations such as p53, POLE and MSI, as well as variants like CTNNB1 that have prognostic value.
    Clinical • Next-generation sequencing
    |
    TP53 (Tumor protein P53) • MSI (Microsatellite instability) • POLE (DNA Polymerase Epsilon) • CTNNB1 (Catenin (cadherin-associated protein), beta 1)
    |
    TP53 mutation • POLE mutation • TP53 expression
    |
    OncoKitDx
    6ms
    Chemotherapy response score (CRS) and efficacy of PARP inhibitor (PARPi) treatment in advanced epithelial ovarian cancer (AEOC) (ESMO-GC 2024)
    22 patients (48%) received PARPi (2 olaparib, 10 niraparib). Due to small sample, we did not find any statistical differences on PFS in the different subgroups. Contrary to expectations, we did observe a tendency of longer PFS in CRS1/2 versus CRS3 for BRCAmut and HRD tumors, indicating no added value for CRS in these situations. In contrast, a tendency of better PARPi response in the CRS3 versus CRS1/2 was noticed in HRP subgroup, suggesting that platinum sensitivity according to CRS could predict a better PARPi response in HRP population.
    Clinical • PARP Biomarker • BRCA Biomarker • Metastases
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    BRCA MASTR Plus Dx • Myriad myChoice® CDx Plus • OncoKitDx
    |
    Lynparza (olaparib) • Zejula (niraparib)
    10ms
    IMPACT OF MOLECULAR STATUS ON CHEMOTHERAPY RESPONSE SCORE (CRS) IN ADVANCED EPITHELIAL OVARIAN CANCER (AEOC) (ESGO 2024)
    Conclusion In our cohort, BRCA1/2-mutated pts and HRD showed a trend towards a better response to NACT as opposed to BRCA-WT and HR proficient pts, according to CRS, although statistical significance is not reached due to the limited number of patients. Further research is guaranteed.
    BRCA Biomarker • Metastases
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1)
    |
    BRCA2 mutation • BRCA1 mutation • ATM mutation • BRCA wild-type • BRIP1 mutation • BRCA mutation
    |
    BRCA MASTR Plus Dx • Myriad myChoice® CDx Plus • OncoKitDx